Discover the latest advances in IgA nephropathy (IgAN) treatments. Tune in for valuable insights from our experts!
Immunoglobulin A nephropathy (IgAN) is the leading cause of glomerulonephritis worldwide. Join renowned experts, Drs. Jürgen Floege, Khalil El Karoui, and Uyen Huynh-Do, as they use insightful case presentations to unravel the latest advances in IgAN treatments and describe innovative approaches to managing patients with IgAN.
Click here to register for the ERA Congress.
13:45 Welcome
13:49 Panel Discussion: Navigating the Evolving Landscape of IgAN: From Current Standards to Real-World Application of Emerging Therapies
14:00 Revolutionizing IgAN Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes (Case Presentation)
14:11 Panel Discussion: Exploring IgAN Treatment Strategies and Future Avenues
14:22 Summary and Take-Home Messages
14:32 Question & Answer Session
14:45: Adjourn
*Subject to change
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Hosts:
Jürgen Floege, MD
Senior Professor
RWTH Aachen University Hospital
Aachen, Germany
Dr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere
Other: Data Safety Monitoring Boards in studies of Novo Nordisk, Visterra
Uyen Huynh-Do, MD
Associate Professor
Division of Nephrology & Hypertension
Inselspital, University Hospital Bern
Bern, Switzerland
Dr. Huynh-Do hasreported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, AstraZeneca, Boehringer, CSL Vifor, GSK, Novartis, Otsuka
Patent Holder: HemoTherapeutics
Faculty:
Khalil El Karoui, MD, PhD
Professor of Nephrology
Tenon Hospital
Sorbonne University
Paris, France
Dr. Karoui has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity is designed to meet the educational needs of the practicing nephrologist.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
This activity is supported by an independent educational grant from CSL Vifor.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Immunoglobulin A nephropathy (IgAN) is the leading cause of glomerulonephritis worldwide. Join renowned experts, Drs. Jürgen Floege, Khalil El Karoui, and Uyen Huynh-Do, as they use insightful case presentations to unravel the latest advances in IgAN treatments and describe innovative approaches to managing patients with IgAN.
Click here to register for the ERA Congress.
13:45 Welcome
13:49 Panel Discussion: Navigating the Evolving Landscape of IgAN: From Current Standards to Real-World Application of Emerging Therapies
14:00 Revolutionizing IgAN Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes (Case Presentation)
14:11 Panel Discussion: Exploring IgAN Treatment Strategies and Future Avenues
14:22 Summary and Take-Home Messages
14:32 Question & Answer Session
14:45: Adjourn
*Subject to change
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Hosts:
Jürgen Floege, MD
Senior Professor
RWTH Aachen University Hospital
Aachen, Germany
Dr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere
Other: Data Safety Monitoring Boards in studies of Novo Nordisk, Visterra
Uyen Huynh-Do, MD
Associate Professor
Division of Nephrology & Hypertension
Inselspital, University Hospital Bern
Bern, Switzerland
Dr. Huynh-Do hasreported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, AstraZeneca, Boehringer, CSL Vifor, GSK, Novartis, Otsuka
Patent Holder: HemoTherapeutics
Faculty:
Khalil El Karoui, MD, PhD
Professor of Nephrology
Tenon Hospital
Sorbonne University
Paris, France
Dr. Karoui has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity is designed to meet the educational needs of the practicing nephrologist.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
This activity is supported by an independent educational grant from CSL Vifor.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
0.75 program credits
Gianluigi Savarese, MD
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
0.75 program creditsJames Burton, MD
Aaron Wong, MD
Summarizing multidisciplinary strategies: Where do we go from here?
Summarizing multidisciplinary strategies: Where do we go from here?
Summarizing multidisciplinary strategies: Where do we go from here?
0.75 program creditsGianluigi Savarese, MD
Clinical choices in managing LDL-c: Where do novel therapies fit in?
0.75 credits 4 episodesProf. Kausik Ray, MBChB, MD, MPhil
Julia Brandts, MD
Pasquale Perrone-Filardi, MD, PhD
Ulrich Laufs, MD, PhD
We're glad to see you're enjoying PACE-CME…
but how about a more personalized experience?
